This metabolic shift repolarized TAMs to the M1 phenotype, resulting in a decrease in interleukin (IL)-10 secretion, which enhanced the immune response of anti-tumor CD8<sup>+</sup> T cells and increased the sensitivity of TNBC to immune checkpoint blockade therapy. The gene discussed is CD8A; the disease is neoplasm.